Abstract
Objective To synthesize findings from systematic reviews and meta-analyses on the efficacy and safety of chloroquine (CQ) and hydroxychloroquine (HCQ) with or without Azithromycin for treating COVID-19, and to update the evidence using a meta-analysis.
Methods A comprehensive search was carried out in electronic databases for systematic reviews, meta-analyses and experimental studies which investigated the efficacy and safety of CQ, HCQ with or without Azithromycin to treat COVID-19. Findings from the reviews were synthesised using tables and forest plots and the quality effect model was used for the updated meta-analysis. The main outcomes were mortality, the need for intensive care services, disease exacerbation, viral clearance and occurrence of adverse events.
Results Thirteen reviews with 40 primary studies were included. Two meta-analyses reported a high risk of mortality, with ORs of 2.2 and 3.0, and the two others found no association between HCQ and mortality. Findings from two meta-analyses showed that HCQ with Azithromycin increased the risk of mortality, with similar ORs of 2.5. The updated meta-analysis of experimental studies showed that the drugs were not effective in reducing mortality (RR 1.1, 95%CI 1.0-1.3, I2 =0.0%), need for intensive care services (OR 1.1, 95%CI 0.9-1.4, I2 =0.0%), virological cure (OR 1.5, 95%CI 0.5-4.4, I2 =39.6%) or disease exacerbation (OR 1.2, 95%CI 0.3-5.9, I2 =31.9%) but increased the odds of adverse events (OR 12,3, 95%CI 2.5-59.9, I2 =76.6%).
Conclusion There is conclusive evidence that CQ and HCQ, with or without Azithromycin are not effective in treating COVID-19 or its exacerbation.
Registration PROSPERO: CRD42020191353
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The is no funding to report
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval was required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
A revised version after peer review has been uploaded
Data Availability
Data are available upon request
Abbreviations
- COVID-19
- Coronavirus Disease-19
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- HCQ
- hydroxychloroquine,
- CQ
- chloroquine
- PRIO-harms
- Preferred Reporting Items for Overviews of Systematic Reviews including harms checklist
- AMSTAR
- Assessing the Methodological Quality of Systematic Reviews
- MASTER
- MethodologicAl STandard for Epidemiological Research
- PRISMA
- Preferred Reporting Items for Systematic Review and Meta-Analysis
- CDSR
- Cochrane Database of Systematic Reviews
- CENTRAL
- Cochrane Central Register of Controlled Trials
- DARE
- Database of Abstracts of Reviews of Effectiveness
